ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN SUPPRESSES PROTHROMBIN ACTIVATION MORE EFFECTIVELY THAN UNFRACTIONATED HEPARIN IN PATIENTS TREATED FOR VENOUS THROMBOEMBOLISM
- 1 June 1997
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 86 (5) , 349-354
- https://doi.org/10.1016/s0049-3848(97)00079-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1995
- Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysisArchives of internal medicine (1960), 1995
- Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosisArchives of internal medicine (1960), 1993
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1992
- EnoxaparinDrugs, 1992
- Low molecular weight heparinBlood, 1992
- A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein ThrombosisThrombosis and Haemostasis, 1991
- HeparinNew England Journal of Medicine, 1991
- Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.Circulation, 1989